Cardiovascular tenders in Africa and South Asia are won on three decisions, and none of them is which molecule to offer. The first is whether you supply single agents or fixed-dose combinations. The second is whether your pack matches how the medicine is actually dispensed — monthly, at a clinic, often without a pharmacist. The third is whether your stability data covers the climate the container is going to. Get those right and the molecule choice mostly follows.
The demand is a treatment-gap problem, not a prevalence problem
The WHO puts the number of adults aged 30–79 living with hypertension at 1.4 billion — a third of that age group — with two-thirds of them in low- and middle-income countries. The numbers that decide procurement volume come next: around 600 million (44%) do not know they have it, roughly the same number are diagnosed and treated, and only about 320 million (23%) have their blood pressure controlled.
That last figure is the one to plan against. A market where 23% of hypertensive patients are controlled is not a market with low demand — it is a market where demand converts into orders only as diagnosis and adherence improve. Every screening drive, every task-shifted clinic, every insurance expansion moves patients from the unaware column into the treated column, and the order book steps up rather than sloping.
For an importer, this has a practical consequence. Cardiovascular volumes in a growing programme are lumpy and revise upward. Contracting for a flat monthly quantity across a year usually leaves you short in the second half.
Combinations are now the mainstream, not the premium tier
In 2023 the WHO added fixed-dose combinations for cardiovascular prevention — commonly called polypills — to its Model List of Essential Medicines, described as cholesterol-lowering agents together with one or more blood-pressure-lowering agents, with or without aspirin. That inclusion matters commercially more than clinically: it gives national formulary committees and donor-funded programmes a reason to list combination products they would previously have treated as branded convenience.
The practical range for an import market therefore looks less like a catalogue of single molecules and more like a short ladder:
• Single antihypertensives at volume — an ACE inhibitor or ARB, a calcium channel blocker, a thiazide-type diuretic. This is where tender quantity concentrates, and where price is set.
• Two-drug antihypertensive combinations — the fastest-growing tier in most South Asian and African private channels, because they halve the tablet count.
• A statin, usually ordered separately and often on a different tender line.
• A prevention combination where the national programme has adopted one.
Most first-time buyers invert this. They ask for a wide combination list because it looks modern, then discover that the single-molecule lines carry 80% of the volume and that they have not priced them competitively.
Stability, not a cold chain, is what these products need
Cardiovascular oral solids do not need a cold chain, which is exactly why buyers stop thinking about temperature — and then lose product in a warehouse at the end of a hot-season shipment.
Two things to insist on. First, long-term stability data generated at 30°C/75% relative humidity — Zone IVb conditions — for the specific pack being supplied, not for the product in general. A blister and an alu-alu pack of the same tablet are different products from a stability standpoint. Second, a shelf life that leaves usable time after arrival. A 24-month product that reaches the central store with 14 months left is fine; one that arrives with seven months left will expire in a district store, and the loss will be recorded against the buyer, not the manufacturer.
Ask for the remaining-shelf-life commitment in writing at the quotation stage. It is a normal clause and its absence is a signal.
Four things to put in a cardiovascular enquiry
1. Volume split between single molecules and combinations. Price the single molecules properly; that is the tender.
2. Pack size chosen from the dispensing model, with a cost-per-treatment-month comparison across at least two options.
3. Zone IVb stability data for the exact pack, plus the minimum remaining shelf life on arrival.
4. Whether a statin line is in scope, since it usually sits on a separate schedule and separate pricing logic.
How Salus approaches cardiovascular supply
Salus Pharmaceuticals manufactures formulations at its WHO-GMP and ISO 9001:2015 certified facility in Baddi, Himachal Pradesh, and cardiovascular care is one of its 21-plus therapeutic categories. Tablets are supplied in blister packs and capsules in alu-alu, and cardiovascular enquiries are quoted across more than one pack configuration because the dispensing model, not the molecule, usually decides whether the order works.
Send the molecule list, the annual volume, the destination market and how the medicine will be dispensed, and we will come back with a costing across pack options.
[View the cardiovascular range →]
Not for publication — production notes
SEO title (60 char target): Cardiovascular Tablets Manufacturer India | Salus Pharma
Meta description (155 char target): Fixed-dose combinations, pack size by dispensing model and Zone IVb stability — what importers and tender cells should specify in a cardiovascular enquiry.
URL slug: /blog/cardiovascular-formulations-import-markets
Internal links to add: cardiovascular product listing · packing capability page · Week 4 Zone IVb stability post · Week 3 diabetes post (pack economics) · enquiry form
Before publishing: – Names drug classes (ACE inhibitor, ARB, calcium channel blocker, thiazide, statin) but no brand names, no dosages and no treatment advice. Still send for QA/regulatory sign-off before publishing. – The pack-size table is a general market observation, not a Salus price list. If you would rather not publish a view on pack sizes, keep the table and delete the sentence recommending 28s/30s. – [CONFIRM: whether Salus currently supplies any fixed-dose cardiovascular combination, and whether a statin line is in the range] — the post does not claim either, but confirm before the sales team fields enquiries from it.
Sources / References
World Health Organization (WHO) – Hypertension
https://www.who.int/news-room/fact-sheets/detail/hypertension
PHRI – Essential Medicines List
https://www.phri.ca/eml/
World Heart Federation – Polypill and WHO Model List of Essential Medicines
https://world-heart-federation.org/news/world-heart-federation-welcomes-landmark-decision-to-include-polypill-in-who-model-list-of-essential-medicines/
Leave a Reply